Join our daily newsletter At The Bell to receive exclusive market insights
- Telix Pharmaceuticals (TLX) announces a number of changes to its executive leadership team to enable the company to move into its next phase of growth
- The company has appointed Darren Smith as Chief Financial Officer, replacing Doug Cubbin from July 31
- Further, Chief Operating Officer Gabriel Liberatore will also step down from his role, effective July 31
- Regional COOs for the Americas, EMEA and APAC regions, and the General Manager of Seneffe, will now lead operations in their respective regions
- A new CEO is appointed for the Americas region with an early Q3 2022 start date in mind, with further details to be available once a commencement date has been set
- Shares in Telix Pharmaceuticals were down 3.22 per cent to $4.51 as of 10:34 am AEST
Telix Pharmaceuticals (TLX) has announced a number of changes to its executive leadership team to enable the company to move into its next phase of growth.
The company has appointed Darren Smith as Chief Financial Officer, replacing Doug Cubbin from July 31.
Mr Smith has over 20 years of executive finance and general management experience, including as Global CFO and Company Secretary at Sirtex Medical.
During his 11-year tenure at Sirtex, he was a key leader during a period of rapid workforce expansion and revenue growth and remained with Sirtex during its acquisition by China Grand Pharma and CPH Genentech in 2018.
Further, Group Chief Operating Officer Gabriel Liberatore will also step down from his role, effective July 31.
As COO, Mr Liberatore delivered on the infrastructure and planning phases for the development of Telix’s manufacturing facility at Seneffe, Belgium and the identification, recruitment and development of regional operating teams to support Telix’s forward commercial activity.
Regional COOs for the Americas, EMEA and APAC regions, and the General Manager of Seneffe, will now lead the operations in their respective regions under the leadership of regional CEOs whilst working closely with global manufacturing, regulatory and quality counterparts.
Telix has also appointed a new CEO for the Americas region has identified an early Q3 2022 start date.
Since February 2022, Group CEO Dr Christian Behrenbruch assumed the role of interim CEO, Telix Americas.
“These leadership changes and new appointments are an immensely positive reflection of our transition to a commercial stage company and are part of our programmed succession planning,” Dr Behrenbruch said.
“Both Doug and Gab have been a key part of Telix’s journey from start-up to launching our first approved product.
“This transition enables Telix to move into the next phase of growth.”
Shares in Telix Pharmaceuticals were down 3.22 per cent to $4.51 as of 10:34 am AEST.
